

**Caspofungin acetate (Caspofungin®)**

**(No. 30/03)**

**Merck Sharpe and Dohme Ltd  
Summary of Recommendation**

7 March 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

**ADVICE**

Caspofungin is not recommended for use within NHS Scotland.

**RECOMMENDATION**

Efficacy and safety data provided to support the possible benefits of caspofungin in the treatment of invasive aspergillosis were extremely limited, and in the form of one small, open-label, uncontrolled study. This evidence is not considered sufficiently robust to justify a recommendation for use at present.

The applicant company has since confirmed that the results of a randomised clinical trial have been published in December 2002. The SMC will provide a further recommendation on this product once an additional submission has been made and assessed.

**Professor David H Lawson  
Chairman**